Trends on epidemiological, virological, and clinical features among newly diagnosed HIV‐1 persons in Northwest Spain over the last 10 years
暂无分享,去创建一个
E. Poveda | S. Pértega | A. Cañizares | Á. Castro‐Iglesias | J. Pedreira | B. Pernas | A. Mena | Marta Grandal
[1] E. Poveda,et al. High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response , 2014, AIDS.
[2] C. Vidal,et al. Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations , 2014, PloS one.
[3] G. Ippolito,et al. The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis , 2013, BMC Infectious Diseases.
[4] A. Brown,et al. Quality of HIV care in the United Kingdom: key indicators for the first 12 months from HIV diagnosis , 2013, HIV medicine.
[5] Hongzhou Lu,et al. Analysis of the immunologic status of a newly diagnosed HIV positive population in China , 2013, BMC Infectious Diseases.
[6] J. Casabona,et al. Who are the men who have sex with men in Spain that have never been tested for HIV? , 2013, HIV medicine.
[7] V. Moyer,et al. Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement , 2013, Annals of Internal Medicine.
[8] M. Chironna,et al. Surveillance of new HIV infections/diagnoses in Puglia region (south Italy), years 2007-2011. , 2013, Annali di igiene : medicina preventiva e di comunita.
[9] B. Suligoi,et al. Late presenters among persons with a new HIV diagnosis in Italy, 2010–2011 , 2013, BMC Public Health.
[10] Y. Yazdanpanah,et al. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Klaus Korn,et al. HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics , 2013, Retrovirology.
[12] H. Salomón,et al. Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina , 2013, Journal of the International AIDS Society.
[13] F. García,et al. Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[14] M. Zazzi,et al. HIV-1 Subtype F1 Epidemiological Networks among Italian Heterosexual Males Are Associated with Introduction Events from South America , 2012, PloS one.
[15] M. Thomson,et al. Rapid expansion of a HIV-1 subtype F cluster of recent origin among men who have sex with men in Galicia, Spain. , 2012, Journal of acquired immune deficiency syndromes.
[16] L. Held,et al. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] Deirdre L Church,et al. HIV-1 viral diversity and its implications for viral load testing: review of current platforms. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[18] M. Leal,et al. Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010 , 2011, Virology Journal.
[19] V. Soriano,et al. Changing rate of non-B subtypes and coinfection with hepatitis B/C viruses in newly diagnosed HIV type 1 individuals in Spain. , 2011, AIDS research and human retroviruses.
[20] David Dunn,et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. , 2011, The Lancet. Infectious diseases.
[21] P. Ghys,et al. Global trends in molecular epidemiology of HIV-1 during 2000–2007 , 2011, AIDS.
[22] Burkhard Morgenstern,et al. The role of recombination in the emergence of a complex and dynamic HIV epidemic , 2010, Retrovirology.
[23] B. Gazzard,et al. Late diagnosis in the HAART era: proposed common definitions and associations with mortality , 2010, AIDS.
[24] A. Mocroft,et al. Medical and Societal Consequences of Late Presentation , 2010, Antiviral therapy.
[25] E. Poveda,et al. Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain. , 2009, AIDS research and human retroviruses.
[26] R. Maserati,et al. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. , 2009, The Journal of antimicrobial chemotherapy.
[27] R. Rodrigues,et al. High prevalence and association of HIV-1 non-B subtype with specific sexual transmission risk among antiretroviral naïve patients in Porto Alegre, RS, Brazil. , 2009, Revista do Instituto de Medicina Tropical de Sao Paulo.
[28] S. Baral,et al. The global epidemic of HIV infection among men who have sex with men , 2009, Current opinion in HIV and AIDS.
[29] T. de Oliveira,et al. Genetic variability of human immunodeficiency virus‐1 in Bahia state, Northeast, Brazil: High diversity of HIV genotypes , 2009, Journal of medical virology.
[30] H. Gunthard,et al. Update of the Drug Resistance Mutations in HIV-1. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[31] A. Tanuri,et al. Drug Resistance Mutation Profile and Accumulation Kinetics in Human Immunodeficiency Virus-Positive Individuals Infected with Subtypes B and F Failing Highly Active Antiretroviral Therapy Are Influenced by Different Viral Codon Usage Patterns , 2008, Antimicrobial Agents and Chemotherapy.
[32] M. Márquez,et al. Prevalencia de mutaciones de resistencia primaria en los nuevos diagnósticos de infección por el VIH en la provincia de Málaga , 2008 .
[33] D. Goldberg,et al. HIV subtypes in Scotland, 2000–2006 , 2007, Epidemiology and Infection.
[34] R. Kaiser,et al. Trends of prevalence of primary HIV drug resistance in Germany. , 2007, The Journal of antimicrobial chemotherapy.
[35] B. Gazzard,et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count , 2007, AIDS.
[36] Atlanta,et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[37] M. Weinstein,et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] JD Lundgren,et al. Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing , 2004, Antiviral therapy.
[39] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[40] G. Ippolito,et al. Association between HIV‐1 infection and miscarriage: a retrospective study , 1998, AIDS.
[41] F. Brun-Vézinet,et al. HIV‐1 diversity in Romania , 1998, AIDS.
[42] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[43] R. Evans. European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[44] V. Soriano,et al. HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. , 2009, AIDS reviews.
[45] Panel de expertos de Gesida,et al. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)]. , 2007 .
[46] U. Bauer,et al. [Centers for Disease Control and Prevention (CDC)]. , 2000, Annales de dermatologie et de venereologie.